The research partner that creates innovative solutions, builds dynamic relationships and enriches your medicines pipeline across a range of human diseases.
Domainex is an award-winning integrated drug discovery research service partner, providing the full range of pre-clinical drug discovery services. They work collaboratively in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. Their team comprises of approximately 70 scientists, who are committed to providing high quality services, and have expertise in:
- Protein production and characterisation
- X-ray crystallography
- Assay development and screening (biochemical, biophysical and cell assays
- Computational chemistry including virtual screening
- Medicinal, synthetic and analytical chemistry
- Fragment- and structure-based drug discovery
Domainex has also established innovative technology platforms enabling them to offer unique services including, Combinatorial Domain Hunting, patented technology to quickly identify soluble, highly expressed domain constructs of proteins by combining semi-random gene fragmentation with efficient screening of the resulting protein fragments.
About Drug Discovery Innovation Programme 2022
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on the adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2022 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2022 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.